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Objective: The aim of this study was to determine the effect of quercetin on the indicators of chronic
systemic inﬂammation (CSI) in stable coronary artery disease (CAD).
Methods: This study included 85 patients with CAD, stable angina pectoris, functional class (FC) II, and heart
failure (=F) 0-y. Each patient was prescribed beta-blockers, statins, and aspirin. In addition, a total of 30
patients, forming the study group received quercetin at a daily dose of 120 mg for two months, while the
remaining 55 patients made up the control group. The levels of cytokines, such as tumor necrosis factor (TNF-
a), interleukin-1b (IL-1b), and interleukin-10 (IL-10) in serum and the expression of the inhibitor of kappa B a
(IkBa) gene in blood mononuclear cells, were determined.
Results: The increased levels of IL-1b and TNF-a, as well as a moderate increase in IL-10 levels, were
detected in the serum of patients with CAD. The expression of the IkBa gene (2–dEt) did not differ
signiﬁcantly betweenthe groups. Under the inﬂuence of quercetin, levels of IL-1b and TNF-a were reduced
and IL-10 levels tended to decrease. In contrast, the serum levels of these cytokines did not change
signiﬁcantly in the control group. The administration of quercetin decreased the expression of the IkBa
gene (0.0092  0.0033 against 0.0261  0.0166, p = 0.003; 2–ddEt, 2.82  1.39 times) in contrast to the
control group.
Conclusion: Quercetin showed anti-inﬂammatory properties in patients with CAD, indicating a decrease in
transcriptional activity of the nuclear factor of transcription kappa B (NF-kB).
© 2018 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chronic systemic inﬂammation (CSI) is an underlying cause of
the development and progression of atherosclerotic vascular
lesions.1 Given the steady increase in the prevalence of coronaryAbbreviations: Akt, protein kinase B a; AMPK, protein kinase activated by
adenosine monophosphate; AP-1, activating protein 1; ASVD, atherosclerosis; BMI,
body mass index; CAD, coronary artery disease; CK, cytokines; COX, cyclooxygen-
ase; CSI, chronic systemic inﬂammation; CVD, cardiovascular diseases; Echo,
Doppler echocardiography; ET, vascular endothelium; FC II, functional class; HF,
heart failure; IkBa, inhibitor of kappa B a; IKKa, IkB-kinase a; IL-10, interleukin-10;
IL-1b, interleukin-1b; LOX, lipoxygenase; LVEF, left ventricular ejection fraction;
MAP3K, protein kinase activated by mitogen 3; NF-kB, nuclear factor of
transcription kappa B; Real-time PCR, real-time polymerase chain reaction; SCORE,
Systematic COronary Risk Evaluation; SIRT1, sirtuin 1; TNFa, tumor necrosis factor;
TRAF6, TNF-a-associated factor 6; W, Watt standard unit of power measurement.
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world, searching for new pathogenetically grounded therapeutic
approaches that impact the inﬂammatory component of athero-
genesis is important.
According to recent research, the polyphenolic compounds of
plant origin exhibit anti-inﬂammatory, antioxidant, endotheliopro-
tective, vasodilative, and many other propertiesare believed to be
promising vasoprotectives.2 One polyphenol is the ﬂavonol
3,5,7,30,40-pentahydroxyﬂavone or quercetin, which is the aglycone
of the glycosiderutin(Fig.1). Quercetinhas antiradical activity due to
the presence of reactive hydroxyl groups in its structure (Fig. 2).
Therefore, it reduces the formation of reactive oxygen species (ROS)
by inhibiting nicotinamide adenine dinucleotide phosphate oxidase
(NADPH oxidase) and xanthine oxidase, decreases the activity of
cyclooxygenase (COX) and lipoxygenase (LOX), and regulates the
activity of intracellular signaling cascades involved in inﬂammatory
reactions.3 The effectiveness of a soluble form of quercetin (Corvitin)
via the i.v. the route in reducing the size of necrosis in acute
myocardial infarction (AMI) and improving left ventricular systolic
function has been proven in patients with congestive heart failure.4,5open access article under the CC BY-NC-ND license (http://creativecommons.org/
he transcriptional activity of NF-kB in stable coronary artery disease,
Table 1
Demographic and clinical characteristics of patients.
Indicator Patients with stable CAD p
Control Group Study Group
Abs. number % Abs. number %
Men 32 58.2 17 56.7 p > 0.05
Women 23 41.8 13 43.3 p > 0.05
Age, X  s 57  8.4 – 54  6.2 – p > 0.05
Duration of CAD 8  5.6 – 7  3.2 – p > 0.05
Smokers 21 38.2 6 20 p < 0.05
Duration of smoking in years, X  s 29  11.7 – 27  10.4 – p > 0.05
Weighed heredity of CVD 42 76.4 21 70 p > 0.05
Presence of HF I stage 28 50.9 17 56.7 p > 0.05
Presence of arterial hypertension y stage low-moderate risk 38 69.1 14 46.7 p < 0.05
Overweight (BMI: 25–29.9 kg/m2) 31 56.3 19 63.3 p > 0.05
Obesity I degree (BMI: 30–34.9 kg/m2) 3 5.5 2 6.7 p > 0.05
Note – CVD: cardiovascular diseases, BMI: body mass index; X: sample mean, s: standard deviation, p: probability.
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quercetin on the indicators of CSI in stable coronary artery disease
(CAD).
2. Materials and methods
The study included 85 patients of both sexes (36 females and 49
males) aged between 48 and 67 years (Table 1). The patients were
selected on the based on the Rose Angina Questionnaire (RAQ), the
SCORE (Systematic COronary Risk Evaluation) scale, the bicycle
ergometer test, and the Doppler echocardiography examination
(echo). According to the requirements of the Declaration of
Helsinki, a written informed consent was obtained from all study
participants.
Signiﬁcant differences between groups of patients were
observed in attitude to smoking and the presence of arterial
hypertension of the ﬁrst stage. Such differences arose as a result
of randomization and did not have a signiﬁcant effect on the
studied indicators. The inclusion criteria were the signs of CAD
such as stable angina pectoris, FC II, etc. The exclusion criteria
were the presence of stage 2 heart failure (HF), stage 2
hypertension, concomitant chronic diseases of the bronchopul-
monary system, liver and kidney dysfunction, endocrine or
allergic disorders, acute musculoskeletal system diseases, cancer,
and thrombophlebitis. The bicycle ergometer test was performed
using a step-by-step protocol of continuously increasing doses of
the physical load with duration of 2 min in each stage. The test
was considered to be “positive” if the occurrence of myocardial
ischemia was objectively evidenced during the test. Each patient
completed a load capacity of 75 W (Watt), corresponding to FC
(functional class) II. The Doppler echocardiography examination
revealed that all patients showed the signs of stage 1 left
ventricular diastolic dysfunction (violation of relaxation type).
The diagnosis of HF was established by the presence of clinical
symptoms such as shortness of breath with exertion, palpitations,
and fatigue as well as a decrease in the left ventricular ejection
fraction (LVEF) within the speciﬁed range. About 39% of theTable 2
Cytokine levels in the blood serum of patients with CAD of both study groups and hea
Group/Mark TNFa, pg/mL 
Patients with CAD of both groups, X  s 8.53  3.24 
Healthy people, Me (conﬁdence interval) 1.6 (0–11) 
Note – X: sample mean, s: standard deviation, Me: median.
Please cite this article in press as: N. Chekalina, et al., Quercetin reduces t
Indian Heart J (2018), https://doi.org/10.1016/j.ihj.2018.04.006patients had LVEF values of 45–50%, corresponding to stage 1 HF
with preserved systolic function, while the remaining 61% of the
patients had LVEF values greater than 50%. The average annual
mortality risk, determined by using the combined assessment of
the SCORE table and the LVEF values, was found to be less than 3%
in selected patients.6 In order to stabilize the clinical course of
CAD, each patient enrolled in the study was prescribed a standard
medication therapy comprising of beta-blockers (5 mg of
bisoprolol once daily in the morning), statins (10 mg of
atorvastatin once daily at bedtime), and 75 mg of aspirin at
bedtime together with lifestyle recommendations such as diet
therapy, dosed physical exertion, and smoking cessation. After a
month of this standardized treatment, the patients were
randomly divided into a study group of 30 patients and a control
group of 55 patients and were examined using clinical and
laboratory methods.
In order to assess the level of CSI, the levels of the cytokines
(CKs) such as tumor necrosis factor (TNF-a), interleukin-1b (IL-
1b), and interleukin-10 (IL-10) were immunoenzymatically
determined in blood, using the test system “Vector-Best”
(Novosibirsk, Russia), which is based on a solid-phase “sand-
wich”variant of the immunoenzymatic analysis with monoclonal
and polyclonal antibodies.7 Using the DT Light DNA ampliﬁer
(DNA Technology, Russia), the expression of the inhibitor of kappa
B a (IkBa) gene in peripheral blood mononuclear cells was
determined by the real-time polymerase chain reaction (real-
time PCR).8 In order to obtain cDNA, a set of reagents was used for
the reverse transcription reaction (syntol, Russia). Total RNA was
isolated from biological samples, using the reagent set “RIBO-zol-
B” (AmpliSens, Russia).The sequences of the primers used for
determining IkBa gene expression were F: 50-GGC TGA AGA AGG
AGC GGC TA-30 and R: 50-CCA TCT GCT CGT ACT CCT CG-30. The
ampliﬁcation conditions were 95.0 C, 5 min for the ﬁrst cycle,
followed 62.0 C for 40 s and 95.0 C for 15 s for 40 cycles. The
“housekeeping” gene, glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) was used as a reference gene (internal control) for
normalizing the expression level of the target gene. Using thelthy people.
IL-1b, pg/mL IL-10, pg/mL
9.46  2.98 10.51  3.33
0.5 (0–6) 5 (0–31)
he transcriptional activity of NF-kB in stable coronary artery disease,
Fig. 1. Chemical structure of rutin(quercetin-3 rutinoside).
Fig. 2. Chemical structure of quercetin.
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calculation was applied for data analysis.
Following the baseline examination, the patients from the
study group were additionally prescribed quercetin at a daily dose
of 120 mg that was divided into three doses per day along with the
basic therapy. On the other hand, the control group continued
taking the basic therapy. The patients did not keep to a special diet.
The consumption of ﬂavonoids as a part of the plant component of
the diet was the same in both groups. The results of this treatment
were evaluated after two months by a similar re-examination.
During the examination and treatment of patients with quercetin,
complications, side effects, allergic reactions or hypersensitivity to
medicines were not found.
All statistical analyses were carried out using the KyPlot
program. The hypothesis of normal distribution was checked by
the Shapiro–Wilk test. Fisher's Criterion was used for comparing
the samples according to the frequency of occurrence of the
trait. Paired Student's t-test was used for comparing the study
groups before and after the treatment. For inappropriate
distribution, the Wilcoxon Signed Rank test and the Steel test
for paired observations were used. Unpaired Student's t-test and
the Steel–Dwass test (nonparametric analog of Tukey's range test)
were used for comparing the data between the study groups.
The relationship between the variables was determined using
Pearson's correlation test or Spearman's and Kendall's rankTable 3
Cytokine levels in the blood serum of the subjects of the study.
Group/Mark Statistical index TNFa, pg/mL 
Before therapy After thera
Control Group X s 8.53  3.24 8.34  2.17 
p = 0.866 
Study Group (quercetin) X s 7.32  2.50 5.74  1.77 
p = 0.060 
Note – X: sample mean, s: standard deviation, p: probability.
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analysis are presented in the form of X  s, where X is the average
value and s is the standard deviation. Due to improper
distribution and characteristics of discontinuous variables, the
data were represented as Me (Q1–Q3), where Me is the median
and Q1 and Q3 are the ﬁrst and the third quartiles, respectively.
Statistical data were considered to be different at a signiﬁcance
level of p < 0.05.9
3. Results
The analysis of CKs in patients with CAD of both groups showed
increased serum levels of IL-1b, TNF-a, and IL-10 (Table 2)10.
After two months of the therapy with quercetin, there was a
decrease in the level of IL–1b in the blood of the patient and also a
decreasing trend for TNFa and IL-10 (p = 0.060 and p = 0.064,
respectively) was noted (Table 3). On the other hand, signiﬁcant
changes in serum CK levels were not found in the control group.
Under the inﬂuence of quercetin, the expression of the IkBa
gene in blood mononuclear cells decreased signiﬁcantly in the
study group relative to the control group (p = 0.003, Table 4).
The results of a correlation analysis, conducted on the markers
of inﬂammation, studied in the patients with CAD, are shown in
Table 5.
Moderate direct correlations between the mRNA levels of the
IkBa gene and the serum levels of TNF-a and IL-10, including a
weak direct correlation between the mRNA levels of the IkBa
gene and the serum levels of IL-1b were revealed. The above
data conﬁrmed the consistency of CK dynamics with the
activation of respective signal transduction cascades. Further-
more, the serum levels of IL-1b and IL-10, as well as those of
TNF-a and IL-10, were found to be moderately correlated.
However, no correlation was found between the levels of IL-1b
and TNF-a in our study.IL-1b, pg/mL IL-10, pg/mL
py Before therapy After therapy Before therapy After therapy
9.46  2.98 7.16  2.98 10.51  3.33 8.72  3.51
p = 0.127 p = 0.134
8.46  3.12 6.14  2.44 9.92  4.08 6.16  3.98
p = 0.008 p = 0.064
he transcriptional activity of NF-kB in stable coronary artery disease,
Table 4
The level of mRNA IkBa expression in peripheral blood mononuclear cells of the subjects of the study.
Group/Mark Statistical index Control Group Study Group (quercetin)
Before treatment After treatment Before treatment After treatment
Expression mRNA IkBa, 2–dEt X s 0.0234  0.0198 0.0253  0.0155 0.0261  0.0166 0.0092*  0.0033
p 0.570 0.003
2–ddEt X (min-max) 0.120 (2.64 to +2.83) 2.817* (5.66 to 1.07)
Note – X: sample mean, s: standard quadratic deviation, (min-max): extreme value variation series, p: probability.
* Signiﬁcant differences between the groups before and after the treatment (p < 0.01).
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The increased levels of proinﬂammatory CKs in terms of
atherogenesis result from the activation of immunocompetent
cells and the endothelium (ET), as evidenced by numerous
scientiﬁc studies.1,11 IL-1b and TNF-a, the two leading mediators
of inﬂammatory response, are synthesized under the inﬂuence of
pathogenic stimuli due to an increase in the transcriptional activity
of the NF-kB gene.1,11 In turn, these CKs support the functioning of
proinﬂammatory signal transduction cascades, involving NF-kB
and activating protein-1 (AP-1) by modulating the activity of
various protein kinases and phosphatases.11,12 IL-1b also activates
the expression of the anti-inﬂammatory CK, IL-10, by the AP-1
signaling pathway that explains the slightly elevated levels of IL-10
observed in patients with CAD.13
Under the inﬂuence of standard medication, no changes were
found in the levels of CKs in the comparison group. Arguably, in our
study, the selected dosage regimen and the period of using statins
were not sufﬁcient to exert their anti-inﬂammatory effects, as
previously found.14 There was no effect of statins on the expression
level of the IkBa gene, which justiﬁes the lack of signiﬁcant
dynamics of CK levels.
NF-kB-dependent mechanisms are the basis of chronic diseases
with constantly high levels of EKs.15 The reduction in the
expression of the IkBa gene under the treatment of quercetin,
which is associated with the decreased transcriptional activity of
NF-kB, is accompanied by the reduced levels of IL-1b in blood.
Taken together, these effects conﬁrm the anti-inﬂammatory
activity of this polyphenol at different levels of signal transduction.
IL-1b is of immense pathogenetic importance in the inﬂammatory
activation of ET. IL-1b is related to TNF receptor-associated factor 6
(TRAF6) action on IkB kinase-a (IKKa), which destroys the
relationship of the dimer NF-kB p50/p65 with IkBa, thereby
leading to the translocation of the p65 subunit into the nucleus
with the transcription of the genes of various inﬂammatory
molecules, including the very same IL-1b. Similar effects
characterize the activation of the mitogen-activated protein kinase
(MAP3K, protein kinase activated by mitogen 3)/AP-1 signaling
pathway, involving IL-1b).11,16,17
As signal transduction by NF-kB stimulates the simultaneous
expression of IkBa, these indicators change unidirectionally.
Brown et al. found that the activation of NF-kB is regulated by aTable 5
Correlation coefﬁcients between the inﬂammatory mediators in patients with
stable coronary artery disease.
mRNA IkBa 0.360** 0.270* 0.382**
IL-10 0.491** 0.377**
IL-1b –
TNFa
TNFa IL-1b IL-10
Note.
* p < 0.05.
** p< 0.01.
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saturated with free NF-kB subunits to form dimers. Following the
restoration of this balance, excess IkBa is quickly degraded.18
Therefore, in our study, the decrease in the expression of the IkBa
gene as well as the serum levels of IL-1b, as determined by the
effects of quercetin, conﬁrm its role as an inhibitor of inﬂammatory
transduction involving NF-kB.
The process of IL-10 expression is associated with the AP-1
signaling pathway in which, activating molecules such as IL-1b
and CD40 ligand from the TNF family can act through their
respective receptors. The activation of NF-kB may be accompanied
by an increase in the anti-inﬂammatory CK, IL-10, as TRAF6 is
involved in all these signaling pathways. However, the inactivation
of NF-kB does not affect the process of IL-10 expression through
the AP-1 signaling pathway, which could explain the lack of
signiﬁcant dynamics of CK levels in our study.13
The recent scientiﬁc studies have shown the effectiveness of
quercetin in activating the protein sirtuin 1 (SIRT1), which makes
the histone backbone denser and prevents the transcription of
genes; this results in different pathogenic effects. Quercetin
inhibits atherosclerotic vascular disease (ASVD) induced by
oxidized low-density lipoprotein mediated endothelial damage
by activating the SIRT1 protein and modulating the AMP-
activated protein kinase (AMPK—activated by adenosine mono-
phosphate)/NADPH oxidase/Akt1 (protein kinase B a)/endothelial
nitric oxide synthase (eNOS) signaling pathways.19,20 In addition
to the proven positive effects of quercetin, such as antioxidant
activity, protection of membranes from oxidative damage by
preventing lipid peroxidation, and enhancing membrane rigidity,
perhaps this mechanism has also inﬂuenced the results of our
study.21 All the above effects support the cardioprotective action
of quercetin.
Of the seven large observational studies conducted between the
years 1961 and 2000, six revealed a reduction in the risk of CAD
when a diet rich in ﬂavonols was consumed.22 The effects of
quercetin, observed in our study at the molecular and epigenetic
levels, can explain some of the mechanisms of its protective action.
5. Conclusion
Thus, unlike statins (atorvastatin), the application of quercetin
basic therapy in patients with stable coronary artery disease
reveals a positive impact on the indicators of chronic systemic
inﬂammation during a two-month treatment period. Quercetin
reduces the levels of IL-1b and, to a lesser extent, TNF-a in blood,
in addition to reducing the levels of IkBa mRNA, thereby indicating
a decrease in the transcriptional activity of NF-kB. Arguably, the
anti-inﬂammatory effects of quercetin may be due to its impact on
the different levels of signal transduction. The results obtained in
our study substantiate the relevance of further studies on the
molecular mechanisms underlying the anti-inﬂammatory activi-
ties of quercetin and its widespread use in the treatment of
coronary artery disease.he transcriptional activity of NF-kB in stable coronary artery disease,
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